KBC Group
IMNM icon

KBC Group’s Immunome IMNM Stock Holding History

KBC Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$59K Hold
2,739
– – ﹤0.01% 1668
2026
Q2 		$58K Hold
2,739
– – ﹤0.01% 1662
2026
Q1 		$60K Buy
+2,739
New +$61K ﹤0.01% 1585
2024
Q2 		– Sell
-1,011
Closed -$25K – 1882
2024
Q1 		$25K Buy
+1,011
New +$20.5K ﹤0.01% 1807

Other funds holding IMNM

Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Mitsubishi UFJ Asset Management (UK)
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $213M AUM 36.38% 1-Year Est. Return
Magnus Financial Group
Magnus Financial Group New York $1.5B AUM 16.47% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Maltin Wealth Management
Maltin Wealth Management Ridgewood, New Jersey $308M AUM 16.5% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GK Wealth Management
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
MB, Levis & Associates
MB, Levis & Associates Center Valley, Pennsylvania $273M AUM 8.08% 1-Year Est. Return

KBC Group's IMNM Position: Q3 2026 in Review

KBC Group held its Immunome (IMNM) position steady in Q3 2026 at 2,739 shares worth $59K. The position accounts for ﹤0.01% of the portfolio, ranked #1668.

KBC Group first reported a position in IMNM in Q1 2024 and has held it in 4 quarters since. The position peaked at $60K in Q1 2026. 18 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

  • KBC Group held 2,739 shares of Immunome worth $59K as of Q3 2026.
  • KBC Group left its Immunome share count unchanged in Q3 2026.
  • Immunome made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1668 holding.
  • KBC Group first reported a position in Immunome in Q1 2024 and has held it in 4 quarters since.
  • KBC Group's Immunome position peaked at $60K in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.